“You did nothing wrong,” said the Department of Public Health contact tracer who called my spouse late on January 2nd, “you wore a mask and followed all the safety guidelines. We may never know ultimately how you got it.” The sentiment brought no relief – our whole family, myself included, now have Covid.
By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. This blog is dedicated to the front-line healthcare workers, essential service workers, scientists, patients, and their families who confront COVID-19 every day, and in reverent remembrance of all of those who have lost their lives to this dread disease.
2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism.
A look back at 2020 and to the future at Atlas Venture.
View the newsletter.
Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Five years later, the Swiss pharma is helping itself to the rest of Cadent’s pipeline in a deal worth $210 million upfront but that could net the latter up to $770 million in total.
Five years after Novartis stepped up with a sizable deal that gave them worldwide rights to Surface Oncology’s lead cancer drug, GlaxoSmithKline is coming in at the other end of the pipeline, snagging a preclinical natural killer drug designed to whip up a more effective attack on cancer cells.